Safe Amgen's Dividend? A Practical Investor's Guide
Amgen's dividend has powered income-focused portfolios for years, but regulatory and pricing challenges raise questio...
A snapshot of the year-to-date total market return for 2024, outlining performance drivers and practical implications for investors.
28,420 articlesAmgen's dividend has powered income-focused portfolios for years, but regulatory and pricing challenges raise questio...
Warren Buffett resurfaces on CNBC as Berkshire Hathaway shares retreat, highlighting leadership transition questions ...
Drones and government funding chatter are reshaping investor sentiment. Ondas is at the center of the action, with ot...
SpaceX IPO buzz is rising, but the hype can mislead older investors. A new market briefing outlines the risks and pra...
A smart way to jump into AI semiconductors starts with a modest, well-balanced plan. Here are three no-brainer AI sto...
Public companies holding Bitcoin are rethinking financing moves as dilution costs start to bite. The era of easy gain...
As chip stocks wobble, there are three AI-focused names that still stand out to me. This guide explains why they matt...
A Phase 3 breakthrough unleashed a dramatic move in Cogent Biosciences. A large fund followed with a sizable stake, s...
A big set of economic moves is at play: jobs data, inflation, and housing trends. This guide explains how nearly mill...
A major stake sale in Arcellx coincides with fresh competition in the field. This analysis breaks down what happened,...
Industry chatter points to a late-2026 filing for a BlackRock XRP ETF, contingent on liquidity and demand. Six XRP ET...
NVIDIA stock hovers in the mid-$170s, as traders debate whether the company can reach $500 per share by 2030 through ...